Litcius/Paper detail

Expression, regulation, and function of PD-L1 on non-tumor cells in the tumor microenvironment

Lingrong Hu, Chengliang Sun, Kai Yuan, Peng Yang

2024Drug Discovery Today23 citationsDOIOpen Access PDF

Abstract

Antiprogrammed death ligand 1 (PD-L1) therapy is a leading immunotherapy, but only some patients with solid cancers benefit. Overwhelming evidence has revealed that PD-L1 is expressed on various immune cells in the tumor microenvironment (TME), including macrophages, dendritic cells, and regulatory T cells, modulating tumor immunity and influencing tumor progression. PD-L1 can also be located on tumor cell membranes as well as in exosomes and cytoplasm. Accordingly, the dynamic expression and various forms of PD-L1 might explain the therapy's limited efficacy and resistance. Herein a systematic summary of the expression of PD-L1 on different immune cells and their regulatory mechanisms is provided to offer a solid foundation for future studies.

Topics & Concepts

Tumor microenvironmentFunction (biology)Cancer researchCell biologyTumor cellsChemistryComputational biologyBiologyCancer Immunotherapy and BiomarkersImmune Cell Function and InteractionImmune cells in cancer
Expression, regulation, and function of PD-L1 on non-tumor cells in the tumor microenvironment | Litcius